These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:
- Galera Therapeutics (GRTX), 208 surge in interest
- Esperion Therapeutics (ESPR), 185% surge in interest
- Appellis Pharmaceuticals (APLS), 150% surge in interest
- Jaguar Health (JAGX), 98% surge in interest
Pipeline and key clinical candidates for these companies:
Galera Therapeutics is focused on developing and commercializing a pipeline of therapeutic candidates that have the potential to transform radiotherapy in cancer. Galera’s selective dismutase mimetic product candidate avasopasem manganese, avasopasem, or GC4419, is being evaluated for radiotherapy-induced toxicities. The company’s second product candidate, rucosopasem manganese, rucosopasem, or GC4711, is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer.
Esperion discovers, develops, and commercializes innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by the status quo.
Apellis Pharmaceuticals says the company "ushered in the first new class of complement medicine in 15 years" with the approval of the first and only targeted C3 therapy. Apellis is advancing this science to "continually develop transformative medicines for people living with rare, retinal, and neurological diseases," it states.
Jaguar Health is a commercial stage pharmaceuticals company focused on developing novel, plant-based, sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Jaguar Health’s wholly owned subsidiary, Napo Pharmaceuticals, focuses on developing and commercializing proprietary plant-based human pharmaceuticals from plants harvested responsibly from rainforest areas. Their crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy.
Recent news on these stocks:
March 16
Citi lowered the firm’s price target on Galera Therapeutics to $12 from $18 and keeps a Buy rating on the shares. The analyst updated the model to reflect the Q4 results.
Northland downgraded Esperion to Underperform from Market Perform with a price target of $1, down from $5. There is uncertainty around the company’s receipt of $300M in milestone payments from partner Daiichi Sankyo Group since the latter disagrees with Esperion’s assessment that the CLEAR Outcomes data supports payment of any milestones upon inclusion of certain required CVRR data in the EU label, the firm noted. The firm cites what it sees as "limited market potential" and the possibility of "significant dilution" in its downgrade.
March 14
In a regulatory filing, Apellis Pharmaceuticals announced it received notification that the FDA is extending the Prescription Drug User Fee Act goal date for the supplemental New Drug Application for the Empaveli Injector. The FDA stated in writing that, "the labeling is still under review at this time and the FDA will miss the goal date of March 15, 2023" The timing of the new PDUFA goal date is still being determined. The Empaveli Injector is an on-body device designed to enhance self-administration of Empaveli, which is approved for adults with paroxysmal nocturnal hemoglobinuria.
About “Biotech Alert”
The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.
This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 15-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.
This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on JAGX:
- Jaguar Health developing AI-powered web portal for Mytesi
- Jaguar Health receives Orphan Drug Designation for crofelemer in MVID
- Jaguar Health receives notice of allowance for U.S. patent
- Jaguar Health reaches 75% enrollement in Phase 3 OnTarget trial of crofelemer
- Jaguar Health announces initial close in private placement financing
